Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913457 · ClinicalTrials.gov registry record
Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients
A clinical trial, sponsored by Echosense.
- Terminated
- Registry status
- 230
- Enrollment target
NCT01913457: Clinical Trial study, sponsored by Echosense.
NCT01913457 is a clinical trial that was terminated before completion, run by Echosense. The registered enrollment target is 230 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01913457 was terminated before completion, sponsored by Echosense.
- TERMINATED
- Registry status
- 230 participants
- Enrollment target
Study Summary
Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD, EchoSense Ltd., Haifa, Israel). These lung Doppler signals (LDS) are in full synchrony with the cardiac cycle and can be obtained from the lungs, including areas remote from the heart and main pulmonary vessels. The LDS waves typically have peak velocities of up to 30 cm/s and are of relatively high power, making it possible to detect them despite the aforementioned attenuation by the air in the lungs. The LDS are thought to represent the radial wall movement of small pulmonary blood vessels, caused by pressure pulse waves of cardiac origin which propagate throughout the lung vasculature. The LDS may contain information of significant diagnostic and physiological value regarding the pulmonary parenchyma and vasculature, as well as the cardio-vascular system in general. Pulmonary arterial hypertension (PAH) is a condition characterized by reshaping of the small pulmonary arteries with increase in pulmonary vascular resistance, leading gradually to right-sided cardiac failure. A trans-thoracic echocardiograph (TTE) is a test classically undertaken in order to screen for pulmonary hypertension. However, the systolic pulmonary artery pressure (SPAP) values thereby obtained are often imprecise and depend upon the expertise of the individual carrying out the test. Therefore, the pulmonary arterial pressure and cardiac output values have to be ascertained with a right-sided cardiac catheterization, which is considered the gold-standard, but is invasive. In a pilot study of adult PAH patients (unpublished), lung Doppler signals have been shown to have the potential to diagnose pulmonary hypertension in two different ways: First, by measuring the degree of attenuation of the LDS during acute pressure rise in the chest cavity (i.e. during Valsalva
Interventions
- RADIATION Ultrasound Doppler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2013-07 |
| Est. Completion | 2021-07-01 |
Why NCT01913457 stopped before completion
NCT01913457 is an observational study that tracks outcomes without assigning an intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ultrasound Doppler is the first listed.
NCT01913457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01913457 about?
NCT01913457 is a clinical study titled "Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients". Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD, EchoSense Ltd., Haifa, Israel). These lung Doppler signals (LDS) are i...
What is the current status of trial NCT01913457?
This trial is currently terminated. The enrollment target is 230 participants. The study started on 2013-07. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT01913457?
The interventions under investigation include: Ultrasound Doppler (RADIATION).
Who is sponsoring clinical trial NCT01913457?
This trial is sponsored by Echosense, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia